New publication – Rare disease

Health technology assessment (HTA) decisions for pharmaceuticals are complex and evolving. New rare disease treatments are often approved more quickly through accelerated approval schemes, creating more uncertainties about clinical evidence and budget impact at the time of market entry. Real-world evidence (RWE), has been suggested as a means to support HTA decisions for rare disease treatments. Read more